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Abstract
Rationale Medication and illicit drugs can have detrimental
side effects which impair driving performance. A drug’s
impairing potential should be determined by well-validated,
reliable, and sensitive tests and ideally be calibrated by bench-
mark drugs and doses. To date, no consensus has been reached
on the issue of which psychometric tests are best suited for
initial screening of a drug’s driving impairment potential.
Objective The aim of this alcohol calibration study is to
determine which performance tests are useful to measure
drug-induced impairment. The effects of alcohol are used to
compare the psychometric quality between tests and as bench-
mark to quantify performance changes in each test associated
with potentially impairing drug effects.
Methods Twenty-four healthy volunteers participated in a
double-blind, four-way crossover study. Treatments were pla-
cebo and three different doses of alcohol leading to blood
alcohol concentrations (BACs) of 0.2, 0.5, and 0.8 g/L.
Results Main effects of alcohol were found in most tests.
Compared with placebo, performance in the Divided
Attention Test (DAT) was significantly impaired after all
alcohol doses and performance in the Psychomotor
Vigilance Test (PVT) and the Balance Test was impaired with
a BAC of 0.5 and 0.8 g/L. The largest effect sizes were found
on postural balance with eyes open and mean reaction time in
the divided attention and the psychomotor vigilance test.
Conclusions The preferable tests for initial screening are the
DAT and the PVT, as these tests were most sensitive to the
impairing effects of alcohol and being considerably valid in
assessing potential driving impairment.
Keywords Driving . Alcohol . Attention . Psychomotor
performance . Cognition . Psychometric tests
Introduction
Many people use drugs other than alcohol (i.e., medicinal and
illicit drugs) which can impair performance (e.g., Vingilis and
Macdonald 2002; Walsh et al. 2004). In Europe, a study,
which was a part of the DRiving Under the Influence of
Drugs, alcohol and medicines (DRUID) project, reported an
estimated prevalence of alcohol use of 3.48 %, illicit drug use
of 1.90 %, impairing medicinal drug use of 1.36 %, and drug-
drug combination of 0.39 % in the general population of
drivers (Houwing et al. 2011). A roadside survey in the
USA indicated that illicit drugs are used by 5.8 %, medicinal
drugs by 4.8 %, and a drug-drug combination by 0.5 % of
weekend drivers (Lacey et al. 2009). Because of the large
number of people involved and the severity of the conse-
quences, one of the most important risks of medicinal and
illicit drug use is that of impaired driving performance and
traffic accidents (e.g., O’Hanlon et al. 1982; O’Hanlon 1984;
Seppala et al. 1979). Therefore, a standardized scientific eval-
uation of potential drug-induced performance impairment is
needed to provide more meaningful warnings to users and
prescribers regarding the impacts of drugs on driving (Kay
and Logan 2011). In addition, there is an increasing demand
from regulatory authorities to provide more information on the
risks of drug-induced impairment of driving. This concerns
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not only newly developed medicinal drugs as part of the
dossier for registration but also marketed and illicit drugs to
determine thresholds for drug concentrations in blood associ-
ated with driving impairment (e.g., Verstraete et al. 2011).
Methodological guidelines for experimental studies
assessing the effects of drugs on driving indicated that rela-
tively simple tests may be used as a first step in screening a
drug’s impairment potential and that more sophisticated pro-
cedures (e.g., driving simulators, on-the-road testing) should
be included in a later stage (ICADTS 1999; Kay and Logan
2011; Vermeeren et al. 1994; Walsh et al. 2008). Among the
more sophisticated tests, the standardized highway driving test
developed by O’Hanlon and colleagues is generally regarded
as the gold standard to measure drug-induced driving impair-
ment (O’Hanlon 1984; Verster and Roth 2011). However, no
consensus has been reached on the specific tests to be used for
initial screening. Such tests have to be widely available, easy
to implement, and relatively cost effective. In order to provide
relevant information, they should be valid with respect to
measuring driving performance supported by theoretical
models of driving (e.g., Michon 1989), have reasonable test-
retest reliability, and be sufficiently sensitive to detect drug-
induced impairment (Kay and Logan 2011;Walsh et al. 2008).
To ensure comparability of results from various research
settings, procedures should be standardized and results cali-
brated by benchmark drugs and doses.
The most well-known and widely used benchmark drug for
assessing drug-induced driving impairment is alcohol
(e.g., González-Wilhelm 2007; Louwerens et al. 1987). The
increased risk of traffic accidents is well established for vari-
ous legal limits of blood alcohol concentrations (BACs).
Although some epidemiological studies found that the risk
of being involved in a fatal crash for drivers at BACs even as
low as 0.2–0.4 g/L is increased (Zador et al. 2000), most
studies found that risks increase exponentially with BACs of
0.5 g/L and higher (e.g., Borkenstein 1964; Krüger 1993;
Schnabel et al. 2010). In line with this, the legal BAC limit
for driving a car is set at a BAC of 0.5 g/L in most countries,
but differences are applicable. For example, the legal limit is
0.2 and 0.8 g/L in Sweden and the UK, respectively. Although
legal limits are societal issues, it is generally agreed that the
impairment produced by BACs of 0.5 g/L and higher is
clinically relevant. Therefore, a BAC of 0.5 g/L can be used
to calibrate performance changes in tests measuring driving-
related skills. Drug effects comparable to those of alcohol with
BACs between 0.5 and 0.8 g/L are generally classified as
moderately severe, whereas drug effects comparable with
BACs over 0.8 g/L are classified as severe.
Review of the literature shows that a number of psycho-
metric tests are preferably used to assess possible driving
impairment, but the choice of tests differs depending on the
area of research or practice. Experimental studies assessing
effects of drugs and alcohol on driving and driving-related
skills in healthy volunteers concluded that tracking perfor-
mance and divided attention, as measured by the Critical
Tracking Test (CTT) and the Divided Attention Test (DAT),
are among the most sensitive tests (e.g., Moskowitz 1973;
Ramaekers et al. 2003; Robbe and O’Hanlon 1995; Verster
and Roth 2011). Clinical trials assessing pharmacokinetics
and pharmacodynamics of new medicinal drugs usually in-
clude the Digit Symbol Substitution Test (DSST) to determine
side effects of various doses on daytime functioning (e.g.,
Greenblatt et al. 2006; Roth et al. 2008). In sleep research,
the Psychomotor Vigilance Test (PVT) is nowadays consid-
ered as gold standard for assessing driver drowsiness resulting
from disturbed or insufficient sleep (e.g., Doran et al. 2001;
Jewett et al. 1999). In the field of aging and dementia, tests
measuring processing speed and cognitive flexibility, such as
the Trail Making Test (TMT) or the Concept Shifting Test
(CST), and Digit Span Test (DST) to measure memory
span, are often considered to be good predictors of on-road-
driving performance (e.g., Clark et al. 2011; Silva et al. 2009).
In the field of neuropsychology, a frequent used test is the
Attention Network Test (ANT) (e.g., Weaver et al. 2009),
because it measures the efficiency of multiple attention net-
works in a relatively short time. Furthermore, balance tests as
part of a Standardized Field Sobriety Test (SFST) are com-
monly used at the roadside by trained policemen (i.e., Drug
Recognition Experts) in the USA and Australia to detect drug-
induced driving impairment (Stuster and Burns 1998).
The list of tests measuring driving-related and drug-
induced impairment is exhaustive. Therefore, not all available
tests could be included; however, we aimed to compare a
number of widely used tests representative for different fields
of research related to driving performance and traffic safety.
The main objective of this study was to compare the relative
sensitivity of these tests for the dose-dependent effects of
alcohol. Since the effects of alcohol are relatively nonspecific
it is expected to affect performance in most tests, in particular
with a BAC of 0.8 g/L.More sensitive tests and parameters are
assumed to show larger effect sizes and significant effects at
lower BACs. A secondary objective was to establish the mean
performance changes in each test associated with three in-
creasing doses of alcohol resulting in BACs of 0.2, 0.5, and
0.8 g/L for future reference and interpretation of the clinical
relevance of drug effects, which could provide a comparison
of a full range of driving-related skills.
Methods
Participants
Twenty-five healthy male and female volunteers (ages 18–
30 years) were recruited through poster advertisements at
Maastricht University. Initial screening was based on a
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medical history questionnaire examined by a medical super-
visor. Accepted participants underwent a physical examina-
tion, which included standard blood hematology and chemis-
try, urinalysis, pregnancy tests, and tests for drugs of abuse
(amphetamines, benzodiazepines, cannabis, cocaine, 3,4-
methylenedioxymethamphetamine, and opiates). For partici-
pation, the following inclusion criteria had to be met: social
drinking, defined as drinking at least three but nomore than 21
glasses of alcohol, per week; and a Body Mass Index (BMI)
between 19 and 29 kg/m2. Exclusion criteria included preg-
nancy or lactation; any history of psychiatric or medical
illness; history or current drug or alcohol abuse; current use
of psychoactive medication; inability to stay abstinent during
the study; excessive caffeine use, defined as drinking six or
more cups of coffee per day; and habitual smoking, defined as
smoking more than seven cigarettes a week.
One participant dropped out after the familiarization ses-
sion for reasons unrelated to treatment. A total of 24 partici-
pants (12 men, 12 women) completed the study. The mean
(±SD) age was 22.7 (±2.3) years and their mean (±SD) BMI
was 22.5 (±2.0) kg/m2. The study was conducted in accor-
dance with the code of ethics on human experimentation
established by the Declaration of Helsinki (1964) and
amended in Seoul (2008). All participants were informed of
the study’s goal, procedures, and potential hazards in writing,
and they indicated their informed consent in writing. The
Medical Ethics Committees of Maastricht University ap-
proved the study. Participants received a financial compensa-
tion for their participation in the study.
Design and alcohol administration
The study was conducted according to a double-blind,
placebo-controlled, four-way crossover design. Treatments
were alcohol doses to reach BACs of 0.0 (i.e., placebo), 0.2,
0.5, and 0.8 g/L. Volunteers participated in two treatment days
during which two doses of alcohol were administered each
day. The first dose was to achieve a low BAC (i.e., 0.0 or
0.2 g/L) and the second dose was to achieve a high BAC (i.e.,
0.5 or 0.8 g/L). The order of test days was balanced over
participants. The washout period was at least 1 week.
The placebo dose consisted of a glass of orange juice with a
small amount (3 mL) of alcohol floating on the surface of the
beverage. This is an effective procedure which indicates that
the beverage contained alcohol (e.g., Fillmore and Vogel-
Sprott 1998). In the other conditions, participants were treated
with several alcohol (97 %) challenges mixed with orange
juice. Alcohol was administered orally. The alcohol dosing
regimen was developed to reach BACs of 0.0, 0.2, 0.5, and
0.8 g/L. To verify this, breath samples were obtained with an
alcohol breathalyzer (Dräger Alcotest 6510). The required
quantity of alcohol to reach the aforementioned BACs
depended on gender and weight of the individual. It was
calculated by an improved version (Watson 1981) of the"
“Widmark formula” (Widmark 1932). Within the improved
formula, the amount of alcohol is related to the individual’s
total body water content. With consideration of the specific
weight of alcohol and the BAC, the necessary quantity is
calculated and divided over two glasses. Participants were
allowed 5 min per glass to consume the drinks. A breath
sample was obtained 10 min after the intake of each glass of
alcohol. If necessary, an additional dose of alcohol was given
to the participant. A breath sample was again obtained before
testing started. Halfway the test session, the BAC was mea-
sured again, and an additional alcohol dose was administered
if BAC had decreased below 0.1 g/L of the required BAC.
Figure 1 indicates a timeline of a testing day.
Procedure
Participants were individually trained to perform the behav-
ioral tests prior to the first test day. The behavioral tests were
conducted twice on two separate days. Tests were always
administered according to the same order: i.e., Concept
Shifting Test, Critical Tracking Test, Divided Attention Test,
Psychomotor Vigilance Test, Digit Symbol Substitution Test,
Digit Span Test, Attention Network Test, and Postural
Balance Test.
During participation in the study, alcohol intake was not
allowed from 24 h prior to each dosing until discharge. On
treatment days, caffeine intake and smoking were not allowed
until discharge. Participants agreed not to use any drugs of
abuse or oral medication (except oral contraceptives and as-
pirin) during the study.
On treatment days, participants fasted for 4 h before arrival
at the lab. Participants yielded urine and breath samples prior
to each test session to confirm their compliance with prohibi-
tions against prior use of drugs and to verify a BAC of 0.0 g/L
at the beginning of each session. Urine samples of women
were examined to exclude pregnancy. A testing day ended at
2100 hours at which time participants were driven home.
Assessment
Critical Tracking Test
The Critical Tracking Test (CTT) measures the ability to
control an unstable error signal in a first-order compensatory
tracking task (Jex et al. 1966). This test is designed to measure
psychomotor coordination. Tracking skills are especially im-
portant at the operational/control level of driving behavior
(e.g., keeping the car in a steady position within the lane).
Participants are instructed to keep an unstable bar in themiddle
of a horizontal plane by counteracting or reverse its move-
ments with the aid of a joystick. The frequency of cursor
deviations at which the participant loses control is the critical
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frequency or lambda (λc, in rad/s). The final score is deter-
mined from the average of all but the lowest and highest scores
in five trails. Total duration of the test is approximately 3 min.
Divided Attention Test
The Divided Attention Test (DAT) measures the ability to
perform two tasks simultaneously (Moskowitz 1973). In the
primary task, the participants perform the same tracking task
described above, set at a constant level of difficulty. In the
other task, the participant monitors 24 peripheral displays in
which single digits change asynchronously at 5-s intervals.
Participants are instructed to remove their foot from a pedal as
rapidly as possible whenever the digit “2” appears. This signal
occurs twice at every location, in random order, at intervals of
5–25 s. Tracking error (DAT-ER, in mm) and average reaction
time to targets (DAT-RT, in ms) are the respective perfor-
mance measures. Duration of the task is 12 min.
Psychomotor Vigilance Test
The Psychomotor Vigilance Test (PVT) is based on a simple
visual reaction time test (Dinges and Powell 1985). The test
measures ability to sustain attention over a period of 10 min.
Participants are required to respond to a visual stimulus pre-
sented at a variable interval (2,000 to 10,000ms) by pressing a
button with the dominant hand. The visual stimulus is a
counter turning on and incrementing from 0 to 60 s at 1-ms
intervals. If a response has not been made in 60 s, the clock
resets and the counter restarts. The reciprocal transform of the
reaction time (1/RT) was calculated because it emphasizes
slowing in the optimum and intermediate response domain
and substantially decreases the contribution of long lapses.
For calculation of mean 1/RT, each RT (ms) was divided by
1,000 and then reciprocally transformed. This measure has
shown to indicate the largest effect sizes when taking mean
reaction times into account (Basner and Dinges 2011).
Attention Network Test
The Attention Network Test (ANT) provides measures of
three functions of attention within a single task: alertness,
orienting, and executive control (Fan et al. 2002). Each trial
begins with the presentation of a fixation cross in the middle
of the computer screen. Participants are instructed to keep
their eyes fixated on the cross throughout the test. Then, at
some variable interval (ranging from 400 to 1,600ms), a cue is
presented for 100 ms. Four hundred milliseconds after the
offset of the cue, a target display appears and remains until
response (i.e., a key-press indicating the direction of the target
arrow), or for 1,700 ms if no response is made. The interstim-
ulus interval is 3,500 ms. There are four cue conditions and
three target conditions. Targets (neutral, congruent, or incon-
gruent) can appear either above or below the fixation cross.
Dependent variables are total reaction time (RT) and differ-
ences between RTs reflecting efficiency of alerting (RT no
cue−RT double cue), orienting (RTcenter cue−RTspatial cue),
and executive networks (RT incongruent flankers−RT con-
gruent flankers). Duration of the test is approximately 25 min.
Digit Symbol Substitution Test
The Digit Symbol Substitution Test (DSST) measures many
different psychomotor and cognitive functions at the same
time (Riedel et al. 2006). A computerized version of the
original paper-and-pencil test (McLeod et al. 1982) taken from
the Wechsler Adult Intelligence Scale is used (e.g., Leufkens
et al. 2009). The participant is required to match each digit
with a symbol from the encoding list as rapidly as possible by
clicking the corresponding response button, using the mouse.
The number of digits encoded correctly within 3 min is the
performance measure.
Concept Shifting Test
The computerized Concept Shifting Test (CST) is used to
measure processing speed and cognitive flexibility (Van der
Elst et al. 2006). It consists of three subtasks (A, B, and C). On
each display, 16 small circles are grouped into one larger
circle. In the smaller circles, the test items appear in a fixed
random order. Participants are asked to cross out numbers (1–
16) in the right order as quickly and accurately as possible,
using a touch screen. In part B, the circles contain letters (A–
P) that have to be crossed out in alphabetical order. In part C,
both numbers and letters are displayed, and the participant is
requested to alternate between numbers and letters. The time
needed to complete each part is scored in seconds (CST-A,
CST-B, and CST-C, respectively). An interference score
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Fig. 1 Timeline in minutes for
alcohol administration, test
performance, and obtaining BAC
samples
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(CSTi) was obtained by the following formula: (CST-C
−½×(CST-A+CST-B))/(½×(CST-A+CST-B))×100. Total
duration of the test is approximately 3 min.
Digit Span Test
The Digit Span Test (DST) measures memory span. It consists
of two parts: one for forward digit span and one for backward
digit span. In the forward part of the DST (Wechsler 1997), the
experimenter reads various series of digits, 1–9, to the partic-
ipant. The series are increased in length by one digit from trial
to trial. Two sequences are presented for each span size. The
instruction is to remember the digits and recall them immedi-
ately in correct serial order. Testing stops when the participant
makes a mistake in both trials of the same span length. In the
backward part of the DST, sequences of numbers are read out
to participants who are asked to repeat them, in reverse order.
The number of sequences correctly recalled forward and
backward is recorded (DST-FW, DST-BW). Total duration
of the test is approximately 2 min.
Postural Balance Test
The Postural Balance Test (PBT) measures the participant’s
ability to maintain balance while standing upright on both
feet. Balance is measured using the AMTI AccuSway
System for Balance and Postural Sway Measurement
(Advanced Mechanical Technology, Inc., Watertown, MA,
USA) force platform (Mets et al. 2010, 2011). Postural sway
is assessed by measuring the length of the path of the center of
pressure (COP) and the area of the 95 % confidence ellipse
enclosing the COP (A95). The test is conducted in two trials of
both 60 s: one trial with the participants’ eyes open and one
trial with eyes closed, both with feet apart at the hip’s width.
Subjective measures
Participants had to describe their subjective feeling in three
dimensions (i.e., alertness, contentedness, and calmness) by
using 16 Visual Analogue Scales (VAS) (Bond and Lader
1974). An additional scale was added on which participants
could indicate their perceived degrees of intoxication. All
scales were administered twice: once before testing started in
a treatment condition and once afterward. After a testing day,
participants were asked to estimate their level of intoxication
(i.e., a BAC of 0.0, 0.2, 0.5, or 0.8 g/L) by a fixed choice
question (i.e., “which BAC do you think we aimed to reach?”)
for both test sessions.
Statistical analyses
Sample size calculation was based on detecting a minimally
relevant difference with an effect size of 0.25 between placebo
and the 0.5 g/L BAC condition. Given a test-retest reliability
of tracking error and reaction time at the Divided Attention
Test of at least r=0.75 (Ramaekers et al. 2011a), a group of
24 participants should permit detection of a mean change in
tracking error and reaction time, with a power of at least 90 %
and an α of 0.05.
First, correlations between the dependent variables from
the eight tests in the placebo condition were calculated to
determine differences or similarities in cognitive processes
measured by each parameter.
Second, alcohol effects on each parameter were analyzed
using general linear model repeated measures with alcohol
(4 levels) as within-subjects factor. Three separate alcohol-
placebo contrasts were conducted when an overall effect of
alcohol was found. Bonferroni adjustment for the number of
tests has been applied to correct for multiple comparisons (α=
0.05/3=0.0167).
Third, difference scores from placebo were calculated for the
three active alcohol conditions to determine mean changes and
95 % confidence intervals for each parameter and alcohol dose.
Fourth, change scores for each of the dependent variables
were transformed to z-scores, whichwere calculated across the
pooled changes in the three active alcohol conditions. This
allows for easy comparison across each of the various perfor-
mance tests (Dry et al. 2012).
Finally, effect sizes were calculated to determine the mag-
nitude of the effects of alcohol, using the effect size (ES)
statistic (i.e., tc[2(1−r) /n]1/2) for repeated measures of
Dunlap et al. (1996). ESs between 0 and 0.2 are considered
small, between 0.2 and 0.7 are considered moderate, and 0.7
or higher are considered large (Falleti et al. 2003). All statis-
tical analyses were done by using the Statistical Package for




Due to technical problems, no data were collected during the
DAT on two occasions and during the CST on a single occa-
sion. Only participants with complete data sets were entered
into the analysis of the respective performance parameter.
Blood alcohol concentrations
Figure 2 shows participants’ mean BAC at each interval when
breath samples were obtained. Participants’ BAC generally
peaked in the ranges of 0.16–0.27 g/L (mean±SD, 0.22±
0.03 g/L), 0.45–0.56 g/L (0.51±0.04 g/L), and 0.70–1.03 g/L
(0.78±0.07 g/L) within 40 min after drinking in the conditions
to reach a BAC of 0.2, 0.5, and 0.8 g/L, respectively.
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Mean BAC declined to 0.03, 0.31, and 0.63 g/L, respec-
tively, over the course of the next 45 min. Booster doses
were then administered to participants in whom the BAC
reached below 0.1 g/L of the appropriate BAC. Mean
BACs of 0.19±0.04, 0.51±0.04, and 0.79±0.06 g/L were
achieved 10 min later, and participants finished testing
45 min later with 0.01±0.03, 0.34±0.05, and 0.64±
0.05 g/L, respectively.
Correlations of performance measures
Correlations between the dependent variables from the eight
tests measured in the placebo conditions showed that most
correlations were low and not significant (−0.4≤r≤0.4).
Absolute values of eight correlations were moderate (i.e.,
varying between 0.41 and 0.57). Performance in the PVT
and DSST each correlated with performance in three other
tests. Both correlated with overall reaction time in the ANT
(r=0.45 and r=−0.46, respectively). In addition, performance
in the PVT correlated with tracking performance in the DAT
(r=0.49) and in the CTT (r=0.48). Performance in the DSST,
on the other hand, correlated additionally with reaction time in
the DAT (i.e., target detection, r=0.52) and with DST-forward
(r=0.46). Finally, tracking performance in the CTT correlated
with tracking error in the DAT (r=−0.41), and the highest
correlation was found between DST-forward and DST-
backward (r=0.57).
Alcohol effects
Table 1 presents a summary of the means and standard errors
of the means (SE) of all performance scores and the results of
the analyses of variance.
A main effect of alcohol was found in tracking perfor-
mance at the CTT (F3,21=5.40, p<0.01). Contrast analysis
revealed a decrease of tracking performance with a BAC of
0.2 g/L (F1,23=6.26, p<0.05) and 0.8 g/L (F1,23=17.57,
p<0.001) compared with placebo. A main effect of alcohol
was found for reaction time at the DAT (F3,19=5.71, p<0.01).
Contrast analysis indicated that this effect on reaction time
was due to all three active alcohol conditions: with a BAC of
0.2 g/L (F1,21=4.40, p<0.05), 0.5 g/L (F1,21=9.53, p<0.01),
and 0.8 g/L (F1,21=16.47, p=0.001) compared with placebo.
For tracking error, a trend was found (F3,21=2.70, p=0.07).
The inverse reaction time (1/RT) at the PVT significantly
differed between alcohol conditions (F3,21=5.74, p<0.01).
Contrast analysis indicated that this effect was due to both
the BACs of 0.5 g/L (F1,23=8.46, p<0.01) and 0.8 g/L (F1,23=
14.12, p=0.001) compared with placebo. Reaction time at the
ANT differed between alcohol conditions (F3,21=9.93,
p<0.001). Reaction time increased with a BAC of 0.8 g/L
(F1,23=19.11, p<0.01) as compared with placebo. No main
effects of alcohol were found at the three different networks.
A main effect of alcohol was found for correct responses at
the DSST (F3,21=11.12, p<0.001). Participants’ correct re-
sponses decreased significantly with a BAC of 0.8 g/L (F1,23=
8.32, p<0.01) compared with placebo.
In the PBT, values of the A95were not normally distributed
and therefore natural log-transformed (e.g., Boyle et al. 2009).
Main effects of alcohol were found in both the eyes open
(F3,21=14.12, p<0.001) and eyes closed condition (F3,21=
6.53, p<0.01). In the eyes open condition, contrast analysis
indicated a trend of A95 with a BAC of 0.2 g/L (F3,21=3.52,
p=0.07) and simple effects with a BAC of 0.5 g/L (F1,23=
13.33, p=0.001) and 0.8 g/L (F1,23=45.74, p<0.001) com-
pared with placebo. In the eyes closed condition, simple
effects were found with a BAC of 0.5 g/L (F1,23=15.15, p=
0.001) and 0.8 g/L (F1,23=12.84, p<0.01) compared with
placebo.
No main effects of alcohol were found at the three subtests
of the Concept Shifting Test (i.e., CST-A, CST-B, and CST-C)
and the interference score and at the two subtests of Digit Span
Test (i.e., forward and backward).
Subjective evaluations
Participants’ ratings of intoxication as measured by two VAS
(i.e., before and after the test battery) differed between alcohol
conditions both before (F3,21=28.49, p<0.001) and after
(F3,21=20.77, p<0.001) testing. Simple contrasts indicated
that participants felt more intoxicated before testing with a
BAC of 0.2 g/L (F1,23=17.05, p<0.001), 0.5 g/L (F1,23=
52.53, p<0.001), and 0.8 g/L (F1,23=81.92, p<0.001) com-
pared with placebo. Simple contrasts indicated that partici-
pants felt more intoxicated after testing with a BAC of 0.2 g/L
(F1,23=13.57, p≤0.001), 0.5 g/L (F1,23=53.56, p≤0.001), and
0.8 g/L (F1,23=59.03, p≤0.001) compared with placebo (see
Fig. 4d for an average of both scales). Participants’ ratings of
alertness differed significantly between BAC conditions
(F3,21=11.86, p<0.001). Participants indicated decreased
alertness in the 0.8 g/L condition (F1,23=13.85, p=0.001) as






















Fig. 2 Mean blood alcohol concentrations (BAC) at each interval when
breath samples were obtained.Capped vertical lines show standard errors
of the mean
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found for subjective contentedness and calmness. The answer
to the question which BAC was aimed for was indicated
correctly on 56 % of the occasions.
Comparison of performance measures
A summary of the mean difference scores with 95 % confi-
dence intervals, mean placebo-normalized z-scores, and
Dunlap’s effect sizes (ES) is shown in Table 2.
Effect sizes and z-scores show that tasks and parameters
differ in sensitivity to the effects of alcohol. The largest effects
were found on postural balance (ES=1.50 and 0.96, for eyes
open and eyes closed, respectively), inverse reaction time in the
PVT (ES=0.70), and reaction time in the DAT (ES=0.65) at a
BAC of 0.8 g/L. Of these tests, only the reaction time in the
DAT showed a significant effect of the lowest BAC (i.e.,
0.2 g/L) with an ES of 0.34. All three tests show strong dose
effects of alcohol, which are moderate to large for a BAC of
0.5 g/L and small to moderate for a BAC of 0.2 g/L (see Fig. 3).
Table 1 Mean (SE), overall treatment effects, and contrast analyses of performance tests







PLA 0.2 g/L 0.5 g/L 0.8 g/L F p p p p
Critical Tracking Test
Lambda (rad/s) 3.77 (0.12) 3.59 (0.14) 3.69 (0.13) 3.46 (0.13) 5.40 <0.01 <0.05 0.24 <0.001
Divided Attention Test
Average error (mm) 15.2 (0.7) 16.0 (0.7) 15.0 (0.7) 17.0 (0.8) 2.70 0.07 0.18 0.73 <0.05
RT (ms) 1,873 (64.0) 1,996 (79.1) 1,988 (62.1) 2,082 (64.1) 5.71 <0.01 <0.05 <0.01 0.001
Psychomotor Vigilance Test
1/RT (ms) 4.05 (0.1) 3.96 (0.1) 3.91 (0.1) 3.75 (0.1) 5.74 <0.01 0.14 <0.01 0.001
RT (ms) 261 (6.6) 268 (9.0) 275 (9.3) 286 (7.9) 6.49 <0.01 0.23 0.01 <0.001
Digit Symbol Substitution Test
Correct responses 99.2 (3.2) 100.8 (2.7) 97.8 (3.0) 93.3 (2.2) 11.12 <0.001 0.57 0.49 <0.01
Attention Network Test
Overall RT (ms) 468 (12.5) 470 (11.1) 473 (13.3) 498 (12.1) 9.93 <0.001 0.74 0.45 0.001
Alerting effect (ms) 63.8 (8.2) 53.6 (5.6) 67.0 (8.5) 75.7 (8.0) 2.25 0.11 0.22 0.72 0.27
Orienting effect (ms) 32.1 (4.8) 32.4 (3.8) 27.1 (4.4) 31.9 (5.1) 0.45 0.72 0.95 0.35 0.98
Conflict effect (ms) 77.8 (8.4) 80.2 (8.1) 86.3 (8.6) 98.9 (8.5) 2.24 0.11 0.64 0.42 0.07
Concept Shifting Test
RT CST-A (s) 20.1 (0.69) 22.5 (0.85) 20.6 (071) 20.4 (0.88) 3.04 0.05 0.02 0.47 0.69
RT CST-B (s) 24.1 (0.77) 23.7 (0.95) 23.4 (0.81) 23.6 (0.80) 0.22 0.88 0.70 0.40 0.64
RT CST-C (s) 28.1 (1.08) 27.8 (1.19) 26.7 (1.11) 27.8 (1.31) 0.39 0.76 0.79 0.32 0.86
Interference (CSTi) 28.1 (4.8) 21.3 (4.9) 22.5 (4.8) 27.2 (5.1) 0.43 0.74 0.36 0.47 0.89
Digit Span Test
Forward—correct 8.1 (0.5) 8.6 (0.4) 8.5 (0.4) 7.9 (0.4) 2.49 0.09 0.09 0.33 0.58
Backward—correct 8.8 (0.4) 8.5 (0.5) 8.5 (0.5) 8.0 (0.4) 1.76 0.19 0.32 0.41 <0.05
Balance Test
A95—eyes open (cm) 0.09 (0.1) 0.28(0.1) 0.54 (0.1) 1.04 (0.1) 14.12 <0.001 0.07 0.001 <0.001
A95—eyes closed (cm) 0.50 (0.1) 0.64 (0.1) 0.87 (0.1) 1.18 (0.2) 6.53 <0.01 0.37 0.001 <0.01
Subjective evaluations
Drunkenness
Before tests 8.3 (2.1) 28.8 (4.2) 39.3 (4.5) 51.3 (4.0) 28.49 <0.001 <0.001 <0.001 <0.001
After tests 10.0 (2.0) 27.5 (4.0) 34.8 (3.7) 45.6 (4.2) 20.77 <0.001 0.001 <0.001 <0.001
Alertness 69.3 (3.2) 64.3 (3.6) 65.6 (3.6) 56.1 (4.0) 11.86 <0.001 0.09 0.23 0.001
Contentedness 79.2 (2.3) 79.5 (2.3) 80.5 (2.5) 81.0 (2.3) 0.83 0.49 0.83 0.29 0.15
Calmness 79.6 (2.7) 76.3 (3.2) 76.0 (3.4) 77.1 (2.6) 1.37 0.28 0.13 0.11 0.30
RT reaction time
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Performance in other tests showed less or no consistent
dose-dependent effects of alcohol. Performance in the DSST
and ANT is only impaired at a BAC of 0.8 g/L, but not by
alcohol at a BAC of 0.5 g/L or less. Performance in the CTT is
impaired but does not show a consistent dose-dependent
increase in the effect (see Fig. 3). Concept Shifting Test and
Digit Span Test performance showed hardly any impairment
(see Fig. 4).
Discussion
The aim of this study was to determine which performance
tests could be useful to measure drug-induced impairment as
an initial screening tool. This was examined by assessing their
ability to detect the effects of various doses of alcohol
resulting in BACs between 0.0 and 0.8 g/L. Eight tests were
included measuring various skills related to driving, such as
psychomotor speed (CTT, ANT, PVT, DSST, DAT), divided
attention (DAT), sustained attention (PVT), spatial attention
(ANT), executive attention (ANT, CST), memory span
(DST), and postural balance (PBT). The results showed that
tasks and parameters varied in their sensitivity to the effects of
alcohol.
All tests except the DST and CST showed statistically
significant effects of alcohol intoxication. In terms of effects
sizes, the largest and strongest dose-dependent effects of
alcohol were found on performance in the PBT, PVT, and
DAT. Only these tests showed significant impairment at a
BAC of 0.5 g/L, the clinically relevant cutoff point as it is
the legal limit for driving under the influence in most coun-
tries. Effect sizes for reaction time in the DAT and PVTwere
moderate (i.e., 0.39 and 0.29, respectively) at a BAC of 0.5 g/L
and large (i.e., 0.65 and 0.70) at a BAC of 0.8 g/L. At the
PBT with eyes open, a large effect size (i.e., 0.77) was found
between placebo and a BAC of 0.5 g/L and a very large effect
size (i.e., 1.50) between placebo and a BAC of 0.8 g/L.
Most of the findings of the present study regarding the
effects of alcohol on performance tests are in line with previ-




















































































































































































Fig. 3 Mean baseline normalized
performance of BACs 0.2, 0.5,
and 0.8 g/L compared with
placebo across dependent
variables of the Critical Tracking
Test, Divided Attention Test,
Psychomotor Vigilance Test, and
Attention Network Test. *p<0.05,
**p<0.01, ***p<0.001. Error
bars indicate the standard error of
the mean
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performance in the DAT, PVT and PBT is sensitive to low or
moderate BACs (e.g., Evans and Levin, 2003, 2004; Howard
et al. 2007; Leung et al. 2012; McCaul et al. 2000; Moskowitz
and Robinson 1988; Moskowitz and Florentino 2000; Ogden
and Moskowitz 2004; Roehrs et al. 2003). Furthermore, the
failure of the CST to show any effects of alcohol is in line with
recent findings that performance in a similar test (i.e., TMT -
part B) was only impaired at a very high BAC (i.e., 1.2 g/L),
but not at lower BACs (i.e., 0.5 and 0.8 g/L) as used in the
present study (Dry et al. 2012). Finally, our finding that the
DSSTshows impairment at a BAC of 0.8 g/L, but not below is
in line with most previous studies. All studies have shown
impairment at BACs of 0.8 g/L or more, but results are not
consistent at BACs between 0.4 and 0.6 g/L ( Brasser et al.
2004; Brumback et al. 2007; Dumont et al., 2008; Evans and
Levin 2003, 2004; Holdstock and de Wit 2001; King and
Byars 2004; McCaul et al. 2000).
Regarding the CTT in the present study, impairment was
found at a BAC of 0.2 and 0.8 g/L, but not at a BAC of 0.5 g/L.
The failure of the CTT to show impairment at a BAC of 0.5
g/L was unexpected. Several studies found impaired tracking
performance at BACs ranging from 0.4 to 0.6 g/L (Kuypers
et al. 2006; Ramaekers et al. 2011b; Vermeeren and O’Hanlon
1998; Vermeeren et al. 2002). Only one study did not find
impairment at a BAC of 0.64 g/L (Simons et al. 2012). Even
though participants were extensively trained in the current
study, a learning effect could have occurred in participants
who completed the 0.5 g/L condition at the end of the second
testing day. Based on previous findings, the CTT should indi-
cate impairment at a BAC of 0.5 g/L, and therefore, this test
should not be excluded as a test for initial screening. However,
quantifying drug effects comparable to various BACs accord-
ing to the present study should be done with caution, as no
alcohol dose-dependent curve at the CTT was found in the
present study.
The results of this study help further research to quantify
drug effects. For example, the hypnotics gaboxadol (15 mg)
and zolpidem (10 mg) taken in the middle of the night were
found to increase reaction time in the DAT the next morning
on average by 184 ms (Leufkens et al. 2009). These effects are
comparable to the effects of a BAC of 0.8 g/L on the same test



















































































































































































Fig. 4 Mean baseline normalized
performance of BACs 0.2, 0.5,
and 0.8 g/L compared with
placebo across dependent
variables of the Digit Symbol
Substitution Test, Concept
Shifting Test, Digit Span Test, and
Postural Balance Test. *p<0.05,
**p<0.01, ***p<0.001. Error
bars indicate the standard error of
the mean
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bedtime in the same study, increased next day reaction time in
the DATon average by 123ms, which is comparable to a BAC
of 0.5 g/L or lower according to the present study. Another
study found a reaction time increase of 95 ms at the PVT for
partial sleep deprivation compared with placebo, which is
comparable to a BAC higher than 0.8 g/L (Bosker et al. 2010).
One of the reasons why the PVT and DAT are more
sensitive to impairment may be related to their longer dura-
tion. The duration of the PVT and DAT is 10 and 12 min,
respectively, whereas many other tests take no more than 2 or
3 min to complete (e.g., DST, CTT, CST, and DSST). Tests of
longer duration may induce a vigilance decrement, which may
enhance the impairing effects of sedative drugs. In shorter
tests, a temporary increase of effort may compensate the
impairing effects. Sensitivity of a test is however not only
determined by its duration, as shown by the relatively small
effects on performance in the longest test in the present study,
the Attention Network Test, which has a duration of approx-
imately 25 min.
One limitation of the present study is that not all available
tests measuring driving-related skills could be included to
compare all these tests in one study. More studies are needed
comparing other tests. Recently, one other study compared six
tests using dose-related effects of alcohol (Dry et al. 2012).
Based on strenghts of dose-dependent effects and effect sizes,
the authors concluded that the Inspection Time test (measur-
ing information processing speed), the Self-Ordered Pointing
Task (measuring working memory) and the Sustained
Attention to Response Task (measuring response inhibition
and cognitive flexibility) were better suited to detect impairing
effects of alcohol than the TMT, the Useful Field of View test,
and a problem solving test.
Furthermore, the question remains how valid laboratory
tests are to assess the domains of driving as proposed by
several researchers. According to Walsh et al. (2008), three
core levels of behavior should be measured to predict crash
risks: (1) automative behavior, (2) control behavior, and (3)
executive planning behavior. Furthermore, five essential driv-
ing ability domains were indicated: (1) alertness/arousal, (2)
attention and processing speed, (3) reaction time/psychomotor
functions, (4) sensory-perceptual functioning, and (5) execu-
tive functions (Kay and Logan 2011). It could be argued that
the DAT is a relatively complex task incorporating all aspects,
whereas the PVT is a relatively simple task which may be
considered to be less sensitive to deficits in executive func-
tioning. When using the PVT, an additional test for executive
function deficits may be needed to cover the most relevant
domains for driving. The validity of the PBT is less clear; it is
not known whether the PBT is a valid measure of actual
driving and whether it can predict actual driving performance.
To predict actual driving impairment, the CTT and DAT have
been found to moderately predict performance at the on-the-
road driving test (Ramaekers 2003; Verster and Roth 2012).
Another aspect is that effects of sedative drugs or sedative
conditions (e.g., sleep deprivation) can be quantified compa-
rable to a particular BAC. Although there are many different
drugs with differing mechanisms of action, one of the most
common drug effects relevant for potential driving impair-
ment is sedation or drowsiness, which is usually associated
with slowing of responses and attentional deficits. It should
however be noted that sedative drugs, sleep deprivation, and
alcohol can have qualitatively different effects, as has been
found previously (e.g., Kleykamp et al. 2010; Tiplady et al.
2003). We are currently exploring the differential effects
of sleep deprivation and sedative drugs on tests measuring
driving-related skills.
In conclusion, the preferable tests for initial screening are
the DATand the PVT, as these tests were most sensitive to the
impairing effects of alcohol and being considerably valid in
assessing potential driving impairment because of sedation or
drowsiness.
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